Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), an innovative
biotechnology company, has set its sights on using its proprietary drug
delivery technology to provide an alternative method of nicotine ingestion that
is safer than smoking. An article further discussing the company reads, “The
technology, known as DehydraTECH(TM), is a patented, cost-effective delivery
mechanism that has been shown to improve the ingestibility of cannabinoids,
vitamins, nonsteroid anti-inflammatory drugs (NSAIDs) and nicotine. Now,
Lexaria has partnered with one of the world’s largest tobacco firms to develop
new, reduced-risk, oral nicotine products using the technology (http://ibn.fm/pddAe). . . . The
deal funds Lexaria’s R&D program — and consumer product development — in
exchange for certain DehydraTECH license rights and a minority equity interest
in Lexaria Nicotine, a wholly owned subsidiary of Lexaria Bioscience Corp. An
initial tranche of $1 million has been provided, with additional phases
providing up to $12 million total. Lexaria has granted a license for its
technology to be used in nicotine-based, oral-format products on an exclusive
basis in the United States and a nonexclusive basis elsewhere globally, for
which it will receive royalties on every dollar of revenue generated utilizing
its technology.”
To view the full article, visit http://ibn.fm/DOyPA
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. has developed and out-licenses its
disruptive delivery technology that promotes healthier ingestion methods, lower
overall dosing and higher effectiveness of lipophilic active molecules. Lexaria
has multiple patents pending in more than 40 countries around the world and has
patents granted in the United States and in Australia for utilization of its DehydraTECH
delivery technology. Lexaria’s technology provides increases in intestinal
absorption rates; more rapid delivery to the bloodstream; and important
taste-masking benefits, for orally administered bioactive molecules including
cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine
and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment